New dose sched­ule for J&J bis­pe­cif­ic; Lay­offs at Ring Ther­a­peu­tics; Re­gen­eron’s pri­or­i­ty re­view

Plus, news about En­ver­ic Bio­sciences and Kazia Ther­a­peu­tics:

John­son & John­son’s bis­pe­cif­ic gets a new dos­ing sched­ule: The FDA ap­proved a re­duced dos­ing reg­i­men for J&J’s mul­ti­ple myelo­ma bis­pe­cif­ic an­ti­body Tec­vayli, the phar­ma com­pa­ny an­nounced Tues­day evening. The re­duced dos­ing ap­proval comes as the drug’s side ef­fects, such as cy­tokine re­lease syn­drome and se­ri­ous in­fec­tions, are sub­stan­tial. The treat­ment is ap­proved for mul­ti­ple myelo­ma pa­tients who have re­ceived four pri­or lines of ther­a­py, but now those who have been in re­mis­sion for at least six months can move down from a week­ly to a bi­week­ly dos­ing sched­ule. — Lei Lei Wu

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER